Abstract
At JADPRO Live 2019, Leslie A. Swanson, ARNP, and Kathleen Boyle,
PA-C, reviewed guideline-concordant molecular testing and therapy in patients with metastatic colorectal cancer (mCRC), the clinical significance of emerging data for existing and novel agents used to treat mCRC, and the management of adverse events associated with mCRC therapies.
